Document Detail

Phytoestrogens and diseases of the prostate gland.
MedLine Citation:
PMID:  10384817     Owner:  NLM     Status:  MEDLINE    
Both benign hyperplasia (BPH) and cancer of the prostate are manifest in men beyond the age of 50. Approximately 50% of men greater than 50 years of age will suffer from the symptoms associated with BPH, especially from bladder outlet obstruction. With the ever-increasing proportion of the population over 65 years of age worldwide, BPH is becoming an important medical problem as the world moves into the next millennium. Cancer of the prostate is the second most commonly diagnosed cancer after skin cancer in the male population of the United States, and the second most common cause of death from cancer after that of the lung. Overall, around the world the incidence of carcinoma of the prostate is increasing annually by 2-3%. Both race and geographical location have a profound influence of the prevalence of prostate cancer worldwide. Black men in the USA have the highest incidence, while the incidence is much lower in Asian men from China, Japan and Thailand. Although the prostate gland is androgen-dependent, it is now recognized that the biological actions of endocrine-related factors, such as androgens, oestrogens, glucocorticoids and certain dietary and environmental factors, are mediated within the gland by various growth regulatory factors. The growth regulatory factors such as epidermal growth factor (EGF), keratinocyte growth factors (KGF), fibroblast growth factors (FGFs) and insulin-like growth factors II and I are mitogenic and directly stimulate cell proliferation under the modulating influence of steroid hormones. Steroids are therefore essential but not directly responsible for cell proliferation. Certain plant compounds such as isoflavonoids, flavonoids and lignans have been proposed as cancer protective compounds in populations with low incidences of prostate diseases. In particular, soya contains the isoflavone genistein, a compound with many properties which could influence both endocrine and growth factor signalling pathways.
K Griffiths; L Denis; A Turkes; M S Morton
Related Documents :
1371457 - Expression of messenger rna for insulin-like growth factors and insulin-like growth fac...
19440287 - New concepts in breast cancer emerge from analyzing clinical data using numerical algor...
24176777 - Nipple areola reconstructing reduction mammaplasty.
1668727 - Growth factor receptors and prostate cell growth.
15765377 - Radioimmunodetection and therapy of breast cancer.
24806617 - P38 mapk inhibits breast cancer metastasis through regulation of stromal expansion.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Baillière's clinical endocrinology and metabolism     Volume:  12     ISSN:  0950-351X     ISO Abbreviation:  Baillieres Clin. Endocrinol. Metab.     Publication Date:  1998 Dec 
Date Detail:
Created Date:  1999-08-19     Completed Date:  1999-08-19     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8704785     Medline TA:  Baillieres Clin Endocrinol Metab     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  625-47     Citation Subset:  IM    
Tenovus Cancer Research Centre, University of Wales College of Medicine, Cardiff, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Estrogens, Non-Steroidal* / administration & dosage,  therapeutic use
Isoflavones / therapeutic use
Lignans / therapeutic use
Plant Preparations
Prostatic Diseases* / epidemiology,  genetics,  prevention & control
Prostatic Hyperplasia / prevention & control
Prostatic Neoplasms / prevention & control
Reg. No./Substance:
0/Estrogens, Non-Steroidal; 0/Isoflavones; 0/Lignans; 0/Phytoestrogens; 0/Plant Preparations

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Epidemiology of phytoestrogens.
Next Document:  Phytoestrogens and inhibition of angiogenesis.